Management of Developmental and Epileptic Encephalopathies

Area of Science:

• Neurology
• Genetics
• Pediatrics

Background:

• Developmental and epileptic encephalopathies (DEEs) are severe, rare epilepsies starting early in life.
• Characterized by drug-resistant seizures, EEG abnormalities, and psychomotor delays, DEEs lead to poor outcomes and increased mortality.
• Comorbidities like intellectual disability and motor dysfunction complicate management and impact quality of life.

Purpose of the Study:

• To review current evidence on managing specific DEEs.
• To highlight the role of targeted therapies and multidisciplinary care in optimizing patient outcomes.
• To discuss evolving treatment approaches driven by genetic advancements.

Main Methods:

• Literature review of current evidence on DEE management.
• Focus on targeted therapies, repurposed antiseizure medications, and surgical interventions.
• Emphasis on managing comorbidities and the importance of multidisciplinary care.

Main Results:

• Treatment of DEEs is challenging due to drug resistance and polypharmacy.
• Advances in genetic testing are enabling more precise therapeutic strategies.
• Multidisciplinary care is crucial for addressing the complex needs of DEE patients.

Conclusions:

• Early recognition and targeted treatments significantly impact neurodevelopmental outcomes and quality of life in DEEs.
• Evolving treatment paradigms include genetic-based therapies and optimized polypharmacy.
• Comprehensive, multidisciplinary care is essential for managing DEEs and their associated comorbidities.